Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

被引:25
|
作者
Lin, Jie [1 ]
Wu, Yongji [2 ]
Yang, Dajun [3 ]
Zhao, Yongqiang [2 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Hematol, Beijing 100853, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Hematol, Beijing 100730, Peoples R China
[3] Ascenta Therapeut Inc, San Diego, CA USA
关键词
multiple myeloma; gossypol acetate; apoptosis; Bcl-2; Bcl-xl; MEDIATED APOPTOSIS; COLON-CARCINOMA; BREAST-CANCER; ORAL GOSSYPOL; CELL-DEATH; DEXAMETHASONE; (-)-GOSSYPOL; EXPRESSION; THERAPY; CYTOTOXICITY;
D O I
10.3892/or.2013.2489
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gossypol is a naturally occurring polyphenolic compound extracted from cotton plants. Recent studies revealed that gossypol is a non-peptidic small molecule inhibitor of Bcl-2/Bcl-xl. The aim of the present study was to investigate the induction of apoptosis and antitumor effects of gossypol acetate in multiple myeloma and the possible mechanism(s) of action. Our results showed that gossypol acetate resulted in a dose- and time-dependent inhibition of multiple myeloma cell proliferation, with an IC50 value to both U266 and Wusl cells at 2.4, 2.2 mu M at 48 h after treatment. Gossypol acetate effectively induced the apoptosis of multiple myeloma cells as demonstrated by typical morphological changes, DNA ladder formation and increase in the percentage of cells in subdiploid peak. Furthermore, colorimetric assays showed activation of both caspase-3 and caspase-9. Bcl-2 and Bcl-xl expression was decreased by 86.5+/-1.2% and 35.9+/-3.6%, respectively, after treatment with gossypol acetate at 25 mu mol/l for 24 h. Preliminary studies in vivo showed that a growth inhibition (TIC) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wusl cells. In addition, there was no body weight loss for the treated group in comparison with the vehicle mice. Our results demonstrated that the potent inhibitor of Bcl-2 and Bcl-xl gossypol acetate had significant antiproliferative and antiapoptotic effects on multiple myeloma cells in vitro and in vivo. Gossypol acetate may represent a promising new anticancer agent with a novel molecular mechanism and warrants further investigation as a single agent, or in combination with other chemotherapeutics, for human multiple myeloma with Bcl-2 overexpression.
引用
收藏
页码:731 / 738
页数:8
相关论文
共 50 条
  • [1] Induction of apoptosis in cancer cells with small molecule inhibitors of Bcl-xL and Bcl-2.
    Shiau, CW
    Yang, CC
    Chen, KF
    Huang, JW
    Chen, CS
    Chen, CS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U196 - U196
  • [2] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Yoshihito Morimoto
    Kimihiko Takada
    Osamu Takeuchi
    Kazuhiro Watanabe
    Masayoshi Hirohara
    Tomoyuki Hamamoto
    Yutaka Masuda
    Molecular and Cellular Biochemistry, 2020, 472 : 187 - 198
  • [3] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Morimoto, Yoshihito
    Takada, Kimihiko
    Takeuchi, Osamu
    Watanabe, Kazuhiro
    Hirohara, Masayoshi
    Hamamoto, Tomoyuki
    Masuda, Yutaka
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 472 (1-2) : 187 - 198
  • [4] Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists
    Wang, SM
    Yang, DJ
    Lippman, ME
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 133 - 142
  • [5] A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    Chauhan, D.
    Velankar, M.
    Brahmandam, M.
    Hideshima, T.
    Podar, K.
    Richardson, P.
    Schlossman, R.
    Ghobrial, I.
    Raje, N.
    Munshi, N.
    Anderson, K. C.
    ONCOGENE, 2007, 26 (16) : 2374 - 2380
  • [6] A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    D Chauhan
    M Velankar
    M Brahmandam
    T Hideshima
    K Podar
    P Richardson
    R Schlossman
    I Ghobrial
    N Raje
    N Munshi
    K C Anderson
    Oncogene, 2007, 26 : 2374 - 2380
  • [7] Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL 1(-)-gossypol] against diffuse large cell lymphoma
    Mohammad, RM
    Wang, SM
    Aboukameel, A
    Chen, B
    Wu, XH
    Chen, JY
    Al-Katib, A
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (01) : 13 - 21
  • [8] The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
    Chen, Jun
    Jin, Sha
    Abraham, Vivek
    Huang, Xiaoli
    Liu, Bernard
    Mitten, Michael J.
    Nimmer, Paul
    Lin, Xiaoyu
    Smith, Morey
    Shen, Yu
    Shoemaker, Alexander R.
    Tahir, Stephen K.
    Zhang, Haichao
    Ackler, Scott L.
    Rosenberg, Saul H.
    Maecker, Heather
    Sampath, Deepak
    Leverson, Joel D.
    Tse, Chris
    Elmore, Steven W.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2340 - 2349
  • [9] Inhibition of Notch enhances pro-apoptotic effect of Bcl-2/Bcl-xL inhibitor in multiple myeloma
    Nefedova, Yulia
    Clifton, Nickolas
    Dalton, William
    Gabrilovich, Dmitry
    CANCER RESEARCH, 2009, 69
  • [10] ABT-737, an inhibitor of Bcl-2/Bcl-XL proteins, is cytotoxic in multiple myeloma cells.
    Kline, M
    Kimlinger, T
    Timm, M
    Haug, J
    Lust, JA
    Rajkumar, SV
    Kumar, S
    BLOOD, 2005, 106 (11) : 455A - 455A